We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
-3.14%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$52.8B
AUM Growth
-$1.34B
(-2.5%)
Cap. Flow
+$1.39B
Cap. Flow
% of AUM
2.62%
Top 10 Holdings %
Top 10 Hldgs %
12%
Holding
4,607
New
780
Increased
956
Reduced
789
Closed
1,336
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$532M |
| 2 |
Wells Fargo
WFC
|
+$480M |
| 3 |
Visa
V
|
+$435M |
| 4 |
Verizon
VZ
|
+$320M |
| 5 |
Broadcom
AVGO
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$547M |
| 2 |
Meta Platforms (Facebook)
META
|
+$525M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$498M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$456M |
| 5 |
Amazon
AMZN
|
+$445M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 18.66% |
| 2 | Technology | 16.35% |
| 3 | Healthcare | 16.13% |
| 4 | Consumer Discretionary | 11.2% |
| 5 | Industrials | 7.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NEWR
151
DELISTED
New Relic, Inc.
NEWR
| $75.4M | 0.14% |
1,127,835
-80,309
| -7% | -$6.57M |
|
152
Snowflake
SNOW
$92.9B
| $74.7M | 0.14% |
326,209
+259,522
| +389% | +$67.1M |
|
153
NextEra Energy
NEE
$187B
| $72.3M | 0.14% |
853,227
+726,872
| +575% | +$58.3M |
|
154
Rio Tinto
RIO
$148B
| $72.2M | 0.14% |
897,737
+299,297
| +50% | +$22.7M |
|
155
Baxter International
BAX
$11.6B
| $71.9M | 0.14% |
926,650
+855,801
| +1,208% | +$71.7M |
|
156
Lumen
LUMN
$6.53B
| $70.5M | 0.13% |
6,253,863
+5,372,303
| +609% | +$61.5M |
|
157
Constellium
CSTM
$3.96B
| $70.5M | 0.13% |
3,915,407
-56,946
| -1% | -$1.04M |
|
158
L3Harris
LHX
$55.9B
| $69.4M | 0.13% |
279,475
+132,196
| +90% | +$30.8M |
|
|
HZNP
159
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $69.2M | 0.13% |
658,106
-998,573
| -60% | -$97.3M |
|
160
GoodRx Holdings
GDRX
$1B
| $69M | 0.13% |
3,569,054
+2,480,556
| +228% | +$56.9M |
|
161
Check Point Software Technologies
CHKP
$13.3B
| $69M | 0.13% |
498,792
+233,991
| +88% | +$30.5M |
|
162
Outfront Media
OUT
$5.64B
| $68.7M | 0.13% |
2,455,702
+58,433
| +2% | +$1.5M |
|
163
Repligen
RGEN
$7.44B
| $68.5M | 0.13% |
364,247
-10,386
| -3% | -$1.97M |
|
164
Mastercard
MA
$477B
| $68.2M | 0.13% |
190,810
+189,152
| +11,408% | +$68M |
|
165
CALL
iShares Russell 2000 ETF
IWM
$80.9B
| $68M | 0.13% |
331,500
-13,900
| -4% | -$2.84M |
|
166
Abbott
ABT
$180B
| $67.5M | 0.13% |
570,266
-680,519
| -54% | -$84.4M |
|
|
MNDT
167
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $67.3M | 0.13% |
3,014,985
-5,071,608
| -63% | -$93.8M |
|
168
CVS Health
CVS
$137B
| $66.4M | 0.13% |
656,112
+235,259
| +56% | +$24.7M |
|
169
DraftKings
DKNG
$11.4B
| $66M | 0.13% |
3,389,716
+3,129,137
| +1,201% | +$66.4M |
|
170
UBS Group
UBS
$170B
| $65.8M | 0.12% |
3,340,397
-1,356,249
| -29% | -$25.7M |
|
171
Entergy
ETR
$54.1B
| $65.4M | 0.12% |
1,119,740
+752,804
| +205% | +$41.2M |
|
172
RTX Corp
RTX
$287B
| $65.1M | 0.12% |
657,000
+656,996
| +16,424,900% | +$62.3M |
|
173
IBM
IBM
$202B
| $64.9M | 0.12% |
499,478
-856,850
| -63% | -$112M |
|
174
Lyft
LYFT
$5.39B
| $64.7M | 0.12% |
1,684,812
+1,239,433
| +278% | +$48.5M |
|
|
AXNX
175
DELISTED
Axonics, Inc. Common Stock
AXNX
| $64M | 0.12% |
1,022,032
+327,700
| +47% | +$17.7M |
|
Similar funds
Marshall Wace's Q1 2022 Portfolio in Review
As of Q1 2022, Marshall Wace held 4,607 positions worth $52.8B, down 2.5% from $54.2B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Marshall Wace's Q1 2022 filing shows 780 new, 956 increased, 789 reduced and 1,336 closed positions. Its largest new stake was Agilent Technologies: 1,082,487 shares worth $143M. The largest sale was Microsoft, an estimated $547M.
By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.
- Marshall Wace's largest Q1 2022 buy was Agilent Technologies: 1,082,487 shares worth $143M.
- Marshall Wace added most to Merck in Q1 2022, an estimated $532M increase.
- Marshall Wace's biggest Q1 2022 reduction was Microsoft, cutting an estimated $547M.
- Marshall Wace fully exited Elevance Health in Q1 2022, selling an estimated $226M.
- Marshall Wace's ten largest holdings make up 12% of its $52.8B portfolio in Q1 2022.
- Marshall Wace opened 780 new positions and closed 1,336 in Q1 2022.
- Marshall Wace's portfolio value fell 2.5% quarter-over-quarter to $52.8B.
Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.